HC Wainwright Has Positive Forecast for GPCR FY2027 Earnings

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) – Analysts at HC Wainwright upped their FY2027 earnings per share (EPS) estimates for Structure Therapeutics in a research report issued on Monday, March 16th. HC Wainwright analyst A. Ghosh now anticipates that the company will post earnings per share of ($2.27) for the year, up from their prior estimate of ($2.34). HC Wainwright currently has a “Buy” rating and a $100.00 target price on the stock. The consensus estimate for Structure Therapeutics’ current full-year earnings is ($0.82) per share. HC Wainwright also issued estimates for Structure Therapeutics’ FY2028 earnings at ($2.37) EPS, FY2029 earnings at ($2.46) EPS and FY2030 earnings at ($2.25) EPS.

Structure Therapeutics (NASDAQ:GPCR) last released its quarterly earnings results on Thursday, February 26th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.14).

A number of other brokerages have also recently issued reports on GPCR. Citizens Jmp reduced their target price on shares of Structure Therapeutics from $120.00 to $113.00 and set a “market outperform” rating for the company in a research report on Friday, February 27th. Jefferies Financial Group set a $125.00 price target on shares of Structure Therapeutics and gave the stock a “buy” rating in a research report on Thursday, December 11th. Citigroup reissued an “outperform” rating on shares of Structure Therapeutics in a report on Friday, December 12th. Leerink Partners restated an “outperform” rating on shares of Structure Therapeutics in a research report on Monday. Finally, BMO Capital Markets set a $145.00 target price on shares of Structure Therapeutics and gave the stock an “outperform” rating in a report on Tuesday. Two analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, Structure Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $110.00.

Structure Therapeutics Price Performance

GPCR stock opened at $51.89 on Wednesday. Structure Therapeutics has a fifty-two week low of $13.22 and a fifty-two week high of $94.90. The stock has a market capitalization of $3.68 billion, a price-to-earnings ratio of -65.68 and a beta of -1.80. The business’s fifty day moving average price is $72.90 and its two-hundred day moving average price is $50.25.

Institutional Investors Weigh In On Structure Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of GPCR. PEAK6 LLC acquired a new stake in Structure Therapeutics during the fourth quarter worth about $553,000. Flax Pond Capital LLC bought a new position in Structure Therapeutics in the 4th quarter valued at about $3,389,000. XTX Topco Ltd acquired a new position in shares of Structure Therapeutics in the 4th quarter valued at approximately $1,335,000. Voloridge Investment Management LLC bought a new stake in shares of Structure Therapeutics during the 4th quarter worth approximately $17,388,000. Finally, Vestal Point Capital LP bought a new stake in shares of Structure Therapeutics during the 4th quarter worth approximately $2,434,000. Institutional investors own 91.78% of the company’s stock.

About Structure Therapeutics

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.